Results 201 to 210 of about 4,450,920 (398)
Box C/D guide RNAs recognize a maximum of 10 nt of substrates [PDF]
, 2016 Zuxiao Yang, Jinzhong Lin, Keqiong Ye
openalex +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
, 2012 Martin Jínek +5 more
openalex +2 more sources
Model-directed generation of CRISPR-Cas13a guide RNAs designs artificial sequences that improve nucleic acid detection [PDF]
, 2023 Sreekar Mantena +6 more
openalex +1 more source
Molecular Oncology, EarlyView.Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra +10 more
wiley +1 more source